Investigation of selected MiRNA as potential biomarker in chronic myeloid leukemia patients.
- 1Department of Medical Laboratory Sciences, Faculty of Allied Medical Sciences, Al-Balqa Applied University, Al-Salt, Jordan.
- 2Department of Medical Laboratory Sciences, Jordan University of Science and Technology, Irbid, Jordan.
- 3Department of Medical Laboratory Sciences, Faculty of Applied Medical Sciences, Al-Ahliyya Amman University, Amman, Jordan.
Abstract
Chronic myeloid leukemia (CML) is a type of blood cancer caused by a genetic abnormality. Meanwhile, circulating microRNAs (miRNAs) are emerging as potential noninvasive cancer biomarkers.This research aims to establish whether miR-192-5p and miR-766-5p provide an accurate assessment of CML diagnosis, and whether these miRNAs have predictive ability on an individual (i.e., independent) and combined basis. One hundred (n=100) study participants (i.e., 50 patients with diagnosed CML and 50 healthy controls) were recruited and consented to study participation. Plasma samples were obtained from all subjects, and miRNA levels were measured using qRT-PCR and analyzed. Group differences were examined, and receiver operating characteristic (ROC) curves and multivariate logistic regression were used for statistical analysis. The plasma of CML participants showed downregulation (p < 0.0001) of both miR-192-5p and miR-766-5p in comparison to control participants. miR-192-5p had good diagnostic performance (i.e., AUC = 0.7958, sensitivity 74%, specificity 72%). However, miR-766-5p had moderate diagnostic performance (i.e., AUC = 0.7164, sensitivity 74%, specificity 64%). In the multivariate logistic regression analysis, miR-192-5p remained a statistically significant, independent CML predictor (OR = 0.48, 95% CI: 0.31-0.69, p < 0.001); whereas, miR-766-5p did not. Smoking status and age (OR = 0.23, p < 0.01) were associated with CML. The combined multivariable model (i.e., plasma miRNA and demographic/clinical variables) yielded enhanced diagnostic performance (AUC = 0.864; sensitivity 86%, specificity 76%, accuracy 81%); thus, the combined model had better discriminative ability than either miRNA alone. Downregulation appeared clearly in both miR-192-5p and miR-766-5p among CML patients. Still, after adjusting for multiple variables, only miR-192-5p kept its predictive strength on its own. Nevertheless, when used together, accuracy increased - shown by an AUC reaching 0.864 - which suggests that combining markers may work better than using one alone.
Related
- PSMD12 is a novel potential biomarker for lung adenocarcinoma and associated with prognosis in lung adenocarcinoma patients.
- The CML/esRAGE ratio as a potential biomarker of early diastolic impairment in asymptomatic type 1 diabetic patients without overt heart disease.
- Host-response biomarker panels for distinguishing selected acute respiratory viral-bacterial co-infections from mono-infections
- Multi-omics profiling identifies triciribine as a biomarker-guided antimetabolite therapy for acute lymphoblastic leukemia.
- Potential role of PDLIM1 in the tumorigenesis of acute myeloid leukemia: a comprehensive bioinformatics and in vitro study
BibTeX
@article{alqaraleh2026investigation,
title = {{Investigation of selected MiRNA as potential biomarker in chronic myeloid leukemia patients.}},
author = {Moath Alqaraleh and Jehad F Alhmoud and Issa I Dababneh and Nada L Odeh and Sarah N Dala-Ali and Leen S Alhiary and Futoon Abedrabbu Al-Rawashde},
journal = {Medicine and pharmacy reports},
year = {2026},
month = oct,
doi = {10.15386/mpr-2984},
url = {https://europepmc.org/article/MED/42997673},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Investigation of selected MiRNA as potential biomarker in chronic myeloid leukemia patients.
AU - Moath Alqaraleh
AU - Jehad F Alhmoud
AU - Issa I Dababneh
AU - Nada L Odeh
AU - Sarah N Dala-Ali
AU - Leen S Alhiary
AU - Futoon Abedrabbu Al-Rawashde
PY - 2026
DA - 2026/10/31
JO - Medicine and pharmacy reports
DO - 10.15386/mpr-2984
UR - https://europepmc.org/article/MED/42997673
AB - Chronic myeloid leukemia (CML) is a type of blood cancer caused by a genetic abnormality. Meanwhile, circulating microRNAs (miRNAs) are emerging as potential noninvasive cancer biomarkers.This research aims to establish whether miR-192-5p and miR-766-5p provide an accurate assessment of CML diagnosis, and whether these miRNAs have predictive ability on an individual (i.e., independent) and combined basis. One hundred (n=100) study participants (i.e., 50 patients with diagnosed CML and 50 healthy controls) were recruited and consented to study participation. Plasma samples were obtained from all subjects, and miRNA levels were measured using qRT-PCR and analyzed. Group differences were examined, and receiver operating characteristic (ROC) curves and multivariate logistic regression were used for statistical analysis. The plasma of CML participants showed downregulation (p < 0.0001) of both miR-192-5p and miR-766-5p in comparison to control participants. miR-192-5p had good diagnostic performance (i.e., AUC = 0.7958, sensitivity 74%, specificity 72%). However, miR-766-5p had moderate diagnostic performance (i.e., AUC = 0.7164, sensitivity 74%, specificity 64%). In the multivariate logistic regression analysis, miR-192-5p remained a statistically significant, independent CML predictor (OR = 0.48, 95% CI: 0.31-0.69, p < 0.001); whereas, miR-766-5p did not. Smoking status and age (OR = 0.23, p < 0.01) were associated with CML. The combined multivariable model (i.e., plasma miRNA and demographic/clinical variables) yielded enhanced diagnostic performance (AUC = 0.864; sensitivity 86%, specificity 76%, accuracy 81%); thus, the combined model had better discriminative ability than either miRNA alone. Downregulation appeared clearly in both miR-192-5p and miR-766-5p among CML patients. Still, after adjusting for multiple variables, only miR-192-5p kept its predictive strength on its own. Nevertheless, when used together, accuracy increased - shown by an AUC reaching 0.864 - which suggests that combining markers may work better than using one alone.
SN - 2602-0807
SN - 2668-0572
ER -